drugset
drugset / Trial / NCT00141518

Long-term Study of Duodopa (Levodopa/Carbidopa) in Advanced Parkinson's: Health Outcomes & Net Economic Impact

NCT00141518 ↗

Phase 4 Completed 77 enrolled AbbVie
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The primary objective of this study is to collect health economic data depicting the initial levels and natural progression over time of resource usage, Parkinson's disease (PD)-related costs, and health related quality of life (HRQoL) for a cohort of advanced PD patients treated with Duodopa (levodopa-carbidopa in an intestinal gel formulation), of which about one-third were Duodopa-naïve prior to the start of the study.

Timeline

Start
2006-03
Primary completion
2011-03
Completion
2011-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Levodopa Small molecule 2 ml Other
Subject Levodopa Small molecule 6 ml Other

Indications

Parkinson disease